insights_auto
Why is BCRX up 2.45%?
Dive Deeperchevron_right
BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$8.14
arrow_upward
+2.45%(+0.20) 1D
Oct 7, 9:45:17 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$7.91
High
$8.16
Low
$7.86
Mkt. cap
2.10B
Avg. vol.
4.95M
Volume
82.34K
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.55
Shares outstanding
255.54M
No. of employees
435
Open
$7.91
High
$8.16
Low
$7.86
Mkt. cap
2.10B
Avg. vol.
4.95M
Volume
82.34K
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.55
Shares outstanding
255.54M
No. of employees
435
News stories
From web sources and news partners
AD HOC NEWS
·
8 hours ago
BioCryst Pharmaceuticals stock fell 1.85 percent on October 6
AD HOC NEWS
·
9 hours ago
BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board
AD HOC NEWS
·
1 day ago
BioCryst Pharmaceuticals stock gets a new science board
Stock Traders Daily
·
1 day ago
Discipline and Rules-Based Execution in BCRX Response
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com